close

Enter

Log in using OpenID

Non-Insulin Therapies for Diabetes Market Revenue Growth Predicted by 2026

embed
Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce enough insulin or is unable to effectively use the insulin it produces.
Non-Insulin Therapies for Diabetes Market Accrues
Phenomenally by 2026 with a Staggering CAGR
Non-Insulin Therapies for Diabetes Market, by Drug Class (Biguanides,
Sulfonylureas Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4
Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2)
inhibitors), by Route of Administration (Oral and Injectable), by Distribution
Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by
Region – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Non-insulin therapies are mostly used in type 2 diabetes patients, where body either does not produce
enough insulin or is unable to effectively use the insulin it produces. Non-insulin-based medication
works with different mechanism of action to reduce blood glucose level and maintain it for optimum
glycemic control. For instance, some agents increase the insulin release from pancreatic cells
(Sulfonylureas), some agents increase glucose uptake by periphery and reduces hepatic glucose output
(Biguanides), some agents slow down digestion of starch in small intestine (alpha glucosidase
inhibitors), and some medication reduces post meal sugar by blocking certain enzymes (Incretin
mimetics). Click To Read More On Non-Insulin Therapies for Diabetes Market.
Non-Insulin Therapies for Diabetes Market Dynamics
Increasing global incidence and prevalence of diabetes is expected to fuel growth of the non-insulin
therapies for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes, which accounts
for around 90% of the global diabetes cases. According to the International Diabetes Federation’s (IDF)
Diabetes Atlas 2017, worldwide prevalence of diabetic patients was around 425 million, of which
around 400 million patients were suffering from type 2 diabetes. As per the World Health Organization
(WHO) 2017 report, diabetes is one of the top 3 causes of death among non-communicable diseases
worldwide, with 114.4 million cases in China, 72.9 million cases in India, and 30.2 million cases in the
U.S.
The global economic burden of diabetes is high and is expected to substantially increase over the
forecast period. According to the American Diabetes Association research in March 2018, the total
costs of diagnosed diabetes have risen to US$ 327 billion in 2017 from US$ 245 billion in 2012.
Therefore, non-insulin therapies for diabetes market is expected to witness growth in the near future.
Moreover, companies are launching new products and combination therapies in the market, which is
expected to drive growth of the global non-insulin therapies for diabetes market. For instance, in 2017,
the Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semiglutide), which is
once a week GLP-1 analog, would increase the patient compliance. In December 2017, FDA approved
the sodium-glucose co-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which is jointly
developed by the Merck & Co. and Pfizer Inc. and in January 2018, the European Medicines Agency
(EMA) granted approval for the same in Europe.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2042
Non-insulin Therapies for Diabetes Market: Competitive Landscape
Key players operating in the global non-insulin therapies for diabetes market include AstraZeneca,
Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F.
Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk,
Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.
Non-insulin Therapies for Diabetes Market: Regional Insights
On the basis of region, the global non-insulin therapies for diabetes market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to
drive growth of the non-insulin therapies for diabetes market due to highest diabetes expenditure in the
U.S. According to the International Diabetes Federation (IDF), in 2017, around 17,100 new cases of
diabetes were detected in the U.S. Asia Pacific is one of the most lucrative region due to increased
diabetes burden in China and India, collectively having over 180 million patients suffering from
diabetes. According to the American Diabetes Association (ADA), rising incidence of type 2 diabetes in
South Asia is likely to be over 150% between 2000 and 2035.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran303   documents Email
Document
Category
Health and Medicine
Views
3
File Size
367 KB
Tags
therapies
1/--pages
Report inappropriate content